Yemaachi Presents Findings on Mutation Profiles of Ghanaian Women with Breast Cancer at AORTIC 2023; Announces Formation of African Clinical Cancer Research Network
Results presented in collaboration with Paemka Research Group at the University of Ghana represent largest sequencing study of its kind conducted entirely in Africa to date; Company’s cancer network will advance and scale precision oncology research and collaborations across the continent
Assessing the utility of liquid biopsy for detecting actionable genetic mutations among indigenous Ghanaian women with metastatic breast cancer.
Liquid biopsy detected multiple actionable variants in Ghanaian women with breast cancer that a tissue-only workflow missed. cfDNA analysis featured less variations in sample preparation which is a key consideration in resource-limited settings.
Global team to study international differences in COVID-19 immunity
Supported by £3.1 million from the Wellcome Trust, the newly-created WWW Consortium links three leading studies in West Africa (Yemaachi Biotech Heritage Study), the West Indies (Windfall Study in Kingston, Jamaica), and West London (the Legacy Study), each tracking how both the virus and our immunity has evolved against COVID-19.
Yemaachi, Africa’s Cancer Research Company, Raises Seed Round To Diversify Genomic Datasets & Advance Precision Oncology Globally
Yemaachi Biotech announced today the close of a $3 million seed round to advance its mission of diversifying precision oncology globally. V8 Capital led the round, with LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital and Ethan Perlstein also participating.